Prediction of delayed treatment response in pulmonary tuberculosis: Use of time to positivity values of Bactec cultures

被引:10
作者
Carroll, N. M. [2 ,3 ]
Uys, P. [2 ,3 ]
Hesseling, A. [3 ]
Lawrence, K. [3 ]
Pheiffer, C. [2 ,3 ]
Salker, F. [3 ]
Duncan, K. [4 ]
Beyers, N. [3 ]
van Helden, P. D. [1 ,2 ,3 ]
机构
[1] Univ Stellenbosch, Fac Hlth Sci, Div Human Genet & Mol Biol, DST NRF Ctr Excellence Biomed TB Res, ZA-7505 Tygerberg, South Africa
[2] Univ Stellenbosch, MRC Ctr Mol & Cellular Biol, ZA-7505 Tygerberg, South Africa
[3] Univ Stellenbosch, Dept Paediat & Child Hlth, Desmond Tutu TB Ctr, ZA-7505 Tygerberg, South Africa
[4] GlaxoSmithKline Res & Dev Ltd, Stevenage, Herts, England
关键词
Tuberculosis; Treatment; Response; Bactec; Time to positivity;
D O I
10.1016/j.tube.2008.03.003
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
New drugs that can shorten tuberculosis (TB) treatment and target drug resistant strains are urgently needed. A test which could predict patients at risk of a delayed response to treatment would facilitate clinical trials of new anti-tuberculosis drugs. A widely-used test for the assessment of response to treatment is sputum smear examination. Patients who are smear positive after 2 and 3 months of treatment are said to have delayed and significantly delayed treatment responses respectively. Time to positivity (TTP) values of Bactec cultures, from the first 2 weeks of treatment were used to predict delayed and significantly delayed treatment responses in patients with first time pulmonary tuberculosis. Changes in TTP values early in treatment were transformed to a response ratio (r). Values of r that were less than a threshold value (r(c)) indicated patients who were at risk of having delayed or significantly delayed response to treatment. Accuracy of prediction was sensitive to the timing of sputum sampling and adherence to therapy in the first 2 weeks. Based on TTP data from the first 2 weeks of treatment, significantly delayed treatment response could be predicted with a sensitivity of 75% and a specificity of 62% while the positive (PPV) and negative predictive values (NPV) were 14% and 97% respectively. White the high NPV indicates that a large proportion of patients with a satisfactory response to treatment can be reliably identified, the tow PPV value underlines the need to use TTP in conjunction with other markers of disease activity to predict unfavourable treatment response in tuberculosis treatment. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:624 / 630
页数:7
相关论文
共 21 条
[1]  
Aber V R, 1978, Bull Int Union Tuberc, V53, P276
[2]   Comparison of quantitative polymerase chain reaction, acid fast bacilli smear, and culture results in patients receiving therapy for pulmonary tuberculosis [J].
Afghani, B ;
Lieberman, JM ;
Duke, MB ;
Stutman, HR .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1997, 29 (02) :73-79
[3]   Progress in tuberculosis vaccine development [J].
Baumann, Sven ;
Eddine, Ali Nasser ;
Kaufmann, Stefan H. E. .
CURRENT OPINION IN IMMUNOLOGY, 2006, 18 (04) :438-448
[4]  
*BECT DICK DIAGN I, 1996, 460TB BACTEC
[5]   Immune markers measured before treatment predict outcome of intensive phase tuberculosis therapy [J].
Brahmbhatt, S. ;
Black, G. F. ;
Carroll, N. M. ;
Beyers, N. ;
Salker, F. ;
Kidd, M. ;
Lukey, P. T. ;
Duncan, K. ;
van Helden, P. ;
Walzl, G. .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2006, 146 (02) :243-252
[6]   Reduction of the rate of false-positive cultures of Mycobacterium tuberculosis in a laboratory with a high culture positivity rate [J].
Carroll, NM ;
Richardson, M ;
Engelke, E ;
de Kock, M ;
Lombard, C ;
van Helden, PD .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2002, 40 (09) :888-892
[7]  
Chierakul N, 2001, Respirology, V6, P305, DOI 10.1046/j.1440-1843.2001.00355.x
[8]   Measurement of sputum Mycobacterium tuberculosis messenger RNA as a surrogate for response to chemotherapy [J].
Desjardin, LE ;
Perkins, MD ;
Wolski, K ;
Haun, S ;
Teixeira, L ;
Chen, Y ;
Johnson, JL ;
Ellner, JJ ;
Dietze, R ;
Bates, J ;
Cave, MD ;
Eisenach, KD .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 160 (01) :203-210
[9]   Progress in TB drug development and what is still needed [J].
Duncan, K .
TUBERCULOSIS, 2003, 83 (1-3) :201-207
[10]  
Enarson D.A., 2000, MANAGEMENT TUBERCULO